Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

Protein kinases have become the second most exploited group of drug targets after G-
protein-coupled receptors (GPCRs), accounting for 30% of drug discovery projects at many …

ABL1 tyrosine-kinase inhibitors (TKI) are front-line therapy for chronic myelogenous
leukaemia and are among the best-known examples of targeted cancer therapeutics …

Pyrimidine (imatinib, dasatinib, nilotinib and pazopanib), pyridine (sorafenib) and pyrrole
(sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted TKIs with high activity towards …

Abstract FOXM1 (Forkhead box M1) is a typical proliferation-associated transcription factor
and is also intimately involved in tumorigenesis. FOXM1 stimulates cell proliferation and cell …

Since its approval in 2001 for frontline management of chronic myelogenous leukemia
(CML), imatinib has proven to be very effective in achieving high remission rates and …

Ischemia and reperfusion (I/R) injury is an often unavoidable consequence of major liver
surgery and is characterized by a sterile inflammatory response that jeopardizes the viability …

Commercially available Pd/C can be used as a catalyst for nitro group reductions with only
0.4 mol% Pd loading. The reaction can be performed using either silane as a transfer …

Over the past decade, a more comprehensive, large-scale approach to studying cancer
genetics and biology has revealed the challenges of tumor heterogeneity, adaption …

Despite advances in cancer detection and prevention, a diagnosis of metastatic disease
remains a death sentence due to the fact that many cancers are either resistant to …